

7. References

1. Austen, K.F., et al., *Chapter IV. Diseases with primary immunologic components*, in *Samter's Immunologic Diseases*. 1995, Lippincott, Williams & Wilkins. p. 667-1223.
2. Cohen, P.L., *Systemic Autoimmunity*, in *Fundamental Immunology*, W.E. Paul, Editor. 1999, Lippincott-Raven Publishers: Philadelphia. p. 1067-1088.
3. Arend, W.P., *The pathophysiology and treatment of rheumatoid arthritis*. *Arthritis Rheum*, 1997. 40(4): p. 595-7.
4. Kouskoff, V., et al., *Organ-specific disease provoked by systemic autoimmunity*. *Cell*, 1996. 87(5): p. 811-22.
5. Matsumoto, I., et al., *Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme*. *Science*, 1999. 286(5445): p. 1732-5.
6. Faik, P., et al., *Mouse glucose-6-phosphate isomerase and neuroleukin have identical 3' sequences*. *Nature*, 1988. 332(6163): p. 455-7.
7. Chaput, M., et al., *The neurotrophic factor neuroleukin is 90% homologous with phosphohexose isomerase*. *Nature*, 1988. 332(6163): p. 454-5.
8. Watanabe, H., et al., *Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide*. *Cancer Res*, 1996. 56(13): p. 2960-3.
9. Xu, W., et al., *The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase*. *Blood*, 1996. 87(11): p. 4502-6.
10. Matsumoto, I., et al., *How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease*. *Nat Immunol*, 2002. 3(4): p. 360-5.
11. Schaller, M., D.R. Burton, and H.J. Ditzel, *Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease*. *Nat Immunol*, 2001. 2(8): p. 746-53.
12. Maccioni, M., et al., *Arthritogenic monoclonal antibodies from K/BxN mice*. *J Exp Med*, 2002. 195(8): p. 1071-7.
13. Edelman, G.M., et al., *The covalent structure of a human gamma G-immunoglobulin. I. Isolation and characterization of the whole molecule, the polypeptide chains, and the tryptic fragments*. *Biochemistry*, 1968. 7(5): p. 1950-8.
14. Tonegawa, S., *Somatic generation of antibody diversity*. *Nature*, 1983. 302(5909): p. 575-81.
15. Janeway, C.A., et al., *The Development of B Lymphocytes*, in *Immunobiology*. 1999, Current Biology Publications: London. p. 195-227.
16. Hardy, R.R., et al., *Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow*. *J Exp Med*, 1991. 173(5): p. 1213-25.
17. Li, Y.S., et al., *Identification of the earliest B lineage stage in mouse bone marrow*. *Immunity*, 1996. 5(6): p. 527-35.
18. Schatz, D.G., M.A. Oettinger, and D. Baltimore, *The V(D)J recombination activating gene, RAG-1*. *Cell*, 1989. 59(6): p. 1035-48.
19. Oettinger, M.A., et al., *RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination*. *Science*, 1990. 248(4962): p. 1517-23.

20. Li, Y.S., K. Hayakawa, and R.R. Hardy, *The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver.* J Exp Med, 1993. 178: p. 951-960.
21. Corbett, S.J., et al., *Sequence of the human immunoglobulin diversity (D) segment locus: a systematic analysis provides no evidence for the use of DIR segments, inverted D segments, "minor" D segments or D-D recombination.* J Mol Biol, 1997. 270(4): p. 587-97.
22. Alt, F.W., et al., *Ordered rearrangement of immunoglobulin heavy chain variable region segments.* Embo J, 1984. 3(6): p. 1209-19.
23. Kerr, W.G., et al., *Mu heavy chains can associate with a pseudo-light chain complex (psi L) in human pre-B cell lines.* Int Immunol, 1989. 1(4): p. 355-61.
24. Tsubata, T. and M. Reth, *The products of pre-B cell-specific genes (lambda 5 and VpreB) and the immunoglobulin mu chain form a complex that is transported onto the cell surface.* J Exp Med, 1990. 172(3): p. 973-6.
25. Karasuyama, H., A. Kudo, and F. Melchers, *The proteins encoded by the VpreB and lambda 5 pre-B cell-specific genes can associate with each other and with mu heavy chain.* J Exp Med, 1990. 172(3): p. 969-972.
26. Gong, S. and M.C. Nussenzweig, *Regulation of an early developmental checkpoint in the B cell pathway by Ig beta.* Science, 1996. 272(5260): p. 411-4.
27. Papavasiliou, F., et al., *The Role of Igβ in Precursor B Cell Transition and Allelic Exclusion.* Science, 1995. 268: p. 408-411.
28. Sanchez, M., et al., *Signal Transduction by Immunoglobulin is Mediated Through Igα and Igβ.* J Exp Med, 1993. 178: p. 1049-1056.
29. Reth, M., et al., *Identification of components of the B cell antigen receptor complex.* Adv Exp Med Biol, 1991. 292: p. 207-14.
30. Weiss, A. and D.R. Littman, *Signal transduction by lymphocyte antigen receptors.* Cell, 1994. 76(2): p. 263-274.
31. Nussenzweig, M.C., et al., *Allelic exclusion in transgenic mice that express the membrane form of immunoglobulin μ.* Science, 1987. 236: p. 816-819.
32. Kitamura, D., et al., *A B cell deficient mouse by targeted disruption of the membrane exons of the immunoglobulin μ chain gene.* Nature, 1991. 350: p. 423-426.
33. Osmond, D.G., *The turnover of B-cell populations.* Immunol Today, 1993. 14(1): p. 34-7.
34. Burnet, M.F., *The Clonal Selection Theory of Acquired Immunity.* Vanderbilt University Press and Cambridge University Press, 1959: p. 209.
35. Talmage, D.W., *Clonal Selection theory.* Science, 1959. 129: p. 1643-1648.
36. Ehrlich, P. and J. Morgenroth, *On Haemolysis: Third Communication; 1900;; in The Collected Papers of Paul Ehrlich,* H. F, Editor. 1956, Pergamon Press: London. p. 205-212.
37. Harrington, W.J., et al., *Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura.* 1951. J Lab Clin Med, 1990. 115(5): p. 636-45.
38. Sandel, P.C. and J.G. Monroe, *Negative selection of immature B cells by receptor editing or deletion is determined by site of antigen encounter.* Immunity, 1999. 10(3): p. 289-99.
39. Pike, B.L., A.W. Boyd, and G.J. Nossal, *Clonal anergy: the universally anergic B lymphocyte.* Proc Natl Acad Sci U S A, 1982. 79(6): p. 2013-7.

40. Goodnow, C.C., et al., *Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice*. Nature, 1988. 334(6184): p. 676-82.
41. Erikson, J., et al., *Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice*. Nature, 1991. 349(6307): p. 331-4.
42. Tsao, B.P., et al., *B cells are anergic in transgenic mice that express IgM anti-DNA antibodies*. Eur J Immunol, 1993. 23(9): p. 2332-9.
43. Fulcher, D.A. and A. Basten, *Reduced life span of anergic self-reactive B cells in a double-transgenic model*. J Exp Med, 1994. 179(1): p. 125-34.
44. Cyster, J.G., S.B. Hartley, and C.C. Goodnow, *Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire*. Nature, 1994. 371(6496): p. 389-95.
45. Chen, C., E.L. Prak, and M. Weigert, *Editing disease-associated autoantibodies*. Immunity, 1997. 6(1): p. 97-105.
46. Braun, U., K. Rajewsky, and R. Pelanda, *Different sensitivity to receptor editing of B cells from mice hemizygous or homozygous for targeted Ig transgenes*. Proc Natl Acad Sci U S A, 2000. 97(13): p. 7429-34.
47. Casellas, R., et al., *Contribution of receptor editing to the antibody repertoire*. Science, 2001. 291(5508): p. 1541-4.
48. Osmond, D.G., *Proliferation kinetics and the lifespan of B cells in central and peripheral lymphoid organs*. Curr Opin Immunol, 1991. 3(2): p. 179-85.
49. Allman, D.M., et al., *Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells*. J Immunol, 1993. 151(9): p. 4431-44.
50. Rolink, A.G., J. Andersson, and F. Melchers, *Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity*. Eur J Immunol, 1998. 28(11): p. 3738-48.
51. Freitas, A.A., M.P. Lembezat, and A. Coutinho, *Expression of antibody V-regions is genetically and developmentally controlled and modulated by the B lymphocyte environment*. Int Immunol, 1989. 1(4): p. 342-54.
52. Gu, H., et al., *Most peripheral B cells in mice are ligand selected*. J Exp Med, 1991. 173(6): p. 1357-71.
53. Viale, A.C., et al., *V region dependent selection of persistent resting peripheral B cells in normal mice*. Int Immunol, 1993. 5(6): p. 599-605.
54. Meffre, E., et al., *Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development*. J Clin Invest, 2001. 108(6): p. 879-86.
55. Wardemann, H., et al., *Predominant autoantibody production by early human B cell precursors*. Science, 2003. 301(5638): p. 1374-7.
56. Hardy, R.R. and K. Hayakawa, *B cell development pathways*. Annu Rev Immunol, 2001. 19: p. 595-621.
57. Casali, P. and A.L. Notkins, *Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes*. Annu Rev Immunol, 1989. 7: p. 513-35.
58. Murakami, M. and T. Honjo, *B-1 cells and autoimmunity*. Ann N Y Acad Sci, 1995. 764: p. 402-9.
59. Meffre, E., M. Chiorazzi, and M.C. Nussenzweig, *Circulating human B cells that express surrogate light chains display a unique antibody repertoire*. J Immunol, 2001. 167(4): p. 2151-6.

60. Meffre, E., et al., *Circulating human B cells that express surrogate light chains and edited receptors*. Nature Immunol., 2000. 1(3): p. 207-213.
61. Wang, Y.H., et al., *Surrogate light chain production during B cell differentiation: differential intracellular versus cell surface expression*. J Immunol, 1998. 161(3): p. 1132-9.
62. Meffre, E., et al., *Antigen receptor engagement turns off the V(D)J recombination machinery in human tonsil B cells*. J Exp Med, 1998. 188(4): p. 765-72.
63. Lemmers, B., et al., *The human (Ψ iL+mu-) proB complex: cell surface expression and biochemical structure of a putative transducing receptor*. Blood, 1999. 93(12): p. 4336-46.
64. Gauthier, L., et al., *Mu-surrogate light chain physicochemical interactions of the human preB cell receptor: implications for VH repertoire selection and cell signaling at the preB cell stage*. J Immunol, 1999. 162(1): p. 41-50.
65. Ueki, Y., et al., *Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus*. J Exp Med, 1990. 171(1): p. 19-34.
66. Ichiyoshi, Y. and P. Casali, *Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments*. J Exp Med, 1994. 180(3): p. 885-95.
67. Steinitz, M., et al., *Continuous production of monoclonal rheumatoid factor by EBV-transformed lymphocytes*. Nature, 1980. 287(5781): p. 443-5.
68. Manheimer-Lory, A.J., et al., *Lupus-specific antibodies reveal an altered pattern of somatic mutation*. J Clin Invest, 1997. 100(10): p. 2538-46.
69. Tarkowski, A., et al., *Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis*. Arthritis Rheum, 1989. 32(9): p. 1087-92.
70. Schellekens, G.A., et al., *Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies*. J Clin Invest, 1998. 101(1): p. 273-81.
71. Pascual, V., et al., *The complete nucleotide sequences of the heavy chain variable regions of six monospecific rheumatoid factors derived from Epstein-Barr virus-transformed B cells isolated from the synovial tissue of patients with rheumatoid arthritis. Further evidence that some autoantibodies are unmutated copies of germ line genes*. J Clin Invest, 1990. 86(4): p. 1320-8.
72. Nemazee, D.A. and K. Bürki, *Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes*. Nature, 1989. 337(February 9): p. 562-566.
73. Hartley, S.B., et al., *Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens*. Nature, 1991. 353(6346): p. 765-9.
74. Chen, C., et al., *The site and stage of anti-DNA B-cell deletion*. Nature, 1995. 373(6511): p. 252-5.
75. Mian, I.S., A.R. Bradwell, and A.J. Olson, *Structure, function and properties of antibody binding sites*. J Mol Biol, 1991. 217(1): p. 133-51.
76. Crouzier, R., T. Martin, and J.L. Pasquali, *Heavy chain variable region, light chain variable region, and heavy chain CDR3 influences on the mono- and polyreactivity and on the affinity of human monoclonal rheumatoid factors*. J Immunol, 1995. 154(9): p. 4526-35.

77. Aguilera, I., et al., *Molecular structure of eight human autoreactive monoclonal antibodies*. Immunology, 2001. 102(3): p. 273-80.
78. Riboldi, P., et al., *Two acquired immunodeficiency syndrome-associated Burkitt's lymphomas produce specific anti-i IgM cold agglutinins using somatically mutated VH4-21 segments*. Blood, 1994. 83(10): p. 2952-61.
79. Brezinschek, H.P., et al., *Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells*. J Clin Invest, 1997. 99(10): p. 2488-501.
80. Dorner, T., et al., *Immunoglobulin kappa chain receptor editing in systemic lupus erythematosus*. J Clin Invest, 1998. 102(4): p. 688-94.
81. Shlomchik, M., et al., *Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation*. J Exp Med, 1990. 171(1): p. 265-92.
82. Li, Z., et al., *Structure-function analysis of a lupus anti-DNA autoantibody: central role of the heavy chain complementarity-determining region 3 Arg in binding of double- and single-stranded DNA*. Eur J Immunol, 2000. 30(7): p. 2015-26.
83. Tanner, J.J., A.A. Komissarov, and S.L. Deutscher, *Crystal structure of an antigen-binding fragment bound to single-stranded DNA*. J Mol Biol, 2001. 314(4): p. 807-22.
84. Bridges, S.L., Jr., et al., *Somatic mutation and CDR3 lengths of immunoglobulin kappa light chains expressed in patients with rheumatoid arthritis and in normal individuals*. J Clin Invest, 1995. 96(2): p. 831-41.
85. Li, H., et al., *Editors and editing of anti-DNA receptors*. Immunity, 2001. 15(6): p. 947-57.
86. Ohnishi, K. and F. Melchers, *The nonimmunoglobulin portion of lambda5 mediates cell-autonomous pre-B cell receptor signaling*. Nat Immunol, 2003. 4(9): p. 849-56.
87. Li, Y., et al., *Anti-DNA B cells in MRL/lpr mice show altered differentiation and editing pattern*. J Exp Med, 2002. 196(12): p. 1543-52.
88. Harindranath, N., et al., *Complete sequence of the genes encoding the VH and VL regions of low- and high-affinity monoclonal IgM and IgA1 rheumatoid factors produced by CD5+ B cells from a rheumatoid arthritis patient*. Int Immunol, 1991. 3(9): p. 865-75.
89. Harindranath, N., et al., *Structure of the VH and VL segments of polyreactive and monoreactive human natural antibodies to HIV-1 and Escherichia coli beta-galactosidase*. Int Immunol, 1993. 5(12): p. 1523-33.
90. Ikematsu, H., et al., *Structural analysis of the VH-D-JH segments of human polyreactive IgG mAb. Evidence for somatic selection*. J Immunol, 1993. 151(7): p. 3604-16.
91. Sanz, I., et al., *Nucleotide sequences of eight human natural autoantibody VH regions reveals apparent restricted use of VH families*. J Immunol, 1989. 142(11): p. 4054-61.
92. Chen, C., et al., *Immunoglobulin heavy chain gene replacement: a mechanism of receptor editing*. Immunity, 1995. 3(6): p. 747-55.
93. Prak, E.L. and M. Weigert, *Light chain replacement: a new model for antibody gene rearrangement*. J Exp Med, 1995. 182(2): p. 541-8.
94. Melamed, D., et al., *Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection*. Cell, 1998. 92(2): p. 173-82.
95. Hertz, M., et al., *V(D)J recombinase induction in splenic B lymphocytes is inhibited by antigen-receptor signalling [see comments]*. Nature, 1998. 394(6690): p. 292-5.

96. Ji, H., et al., *Arthritis critically dependent on innate immune system players.* Immunity, 2002. 16(2): p. 157-68.
97. Friedlander, R.M., M.C. Nussenzweig, and P. Leder, *Complete Nucleotide Sequence of the Membrane form of the Human IgM Heavy Chain.* Nucleic Acids Research, 1990. 18: p. 4278.